ROSALIND ADVISORS INC
Q3 2026 Form 13-F
TORONTO, ONTARIO, CANADA
CIK 0001622627
· Institutional investment manager
$311.9M Reported Value Total
Reported value
$311.9M
Quarter over quarter
+8.7%
Holdings
35
Top-10 concentration
71.6%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Steven Salamon
President, Rosalind Advisors, Inc.
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2026 13F record
Q3 2026 13F filing summary
| Period of report | September 30, 2026 |
|---|---|
| Filed | November 16, 2026 |
| Form | 13F-HR |
| Reported value | $311.9M |
| Positions | 35 |
| Change in reported value | +15.9% |
| New positions | 7 |
| Exited positions | 1 |
| Position turnover | 22.2% |
| Top-10 concentration | 71.6% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
35 | $311.9M |
|
Q2 2026 13F
Filed Aug 14, 2026
|
29 | $269.2M |
|
Q1 2026 13F
Filed May 14, 2026
|
32 | $248.9M |
|
Q4 2025 13F
Filed Feb 12, 2026
|
29 | $284.5M |
|
Q3 2025 13F
Filed Nov 13, 2025
|
29 | $292.6M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
29 | $210.9M |
|
Q1 2025 13F
Filed May 14, 2025
|
31 | $205.6M |
|
Q4 2024 13F
Filed Feb 11, 2025
|
28 | $195.6M |
|
Q3 2024 13F
Filed Oct 30, 2024
|
29 | $156.2M |
|
Q2 2024 13F
Filed Jul 12, 2024
|
35 | $130.0M |
|
Q1 2024 13F
Filed Apr 25, 2024
|
31 | $107.0M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
27 | $121.4M |
Top 20 holdings · Q3 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | DCTH DELCATH SYSTEMS, INC. | $52.7M | 16.9% |
| 2 | VSTM VERASTEM INC | $34.1M | 10.94% |
| 3 | FENC FENNEC PHARMACEUTICALS INC | $34.0M | 10.89% |
| 4 | XERS XERIS BIOPHARMA HOLDINGS INC | $24.7M | 7.92% |
| 5 | CYBN CYBIN INC | $17.1M | 5.47% |
| 6 | SVRA SAVARA INC | $16.4M | 5.26% |
| 7 | REPL REPLIMUNE GROUP INC | $13.2M | 4.25% |
| 8 | VOR VOR BIOPHARMA INC | $11.6M | 3.73% |
| 9 | MDWD MEDIWOUND LTD | $10.3M | 3.31% |
| 10 | XFOR X4 PHARMACEUTICALS INC | $9.3M | 2.99% |
| 11 | AQST AQUESTIVE THERAPEUTICS INC | $9.3M | 2.97% |
| 12 | PCVX VAXCYTE INC | $8.5M | 2.72% |
| 13 | TARA PROTARA THERAPEUTICS INC | $7.3M | 2.35% |
| 14 | MYO MYOMO INC | $6.1M | 1.96% |
| 15 | BCRX BIOCRYST PHARMACEUTICALS INC | $6.0M | 1.93% |
| 16 | RCKT ROCKET PHARMACEUTICALS INC | $5.8M | 1.86% |
| 17 | PEPG PEPGEN INC | $4.8M | 1.55% |
| 18 | PROF PROFOUND MEDICAL CORP | $4.8M | 1.54% |
| 19 | TLPH TALPHERA INC | $4.8M | 1.54% |
| 20 | NRXS NEURAXIS INC | $4.0M | 1.3% |
Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.